These tools may be used for doctor-patient communication or educational or research purposes.

Researcher resources

Scientific publications on personalized medicine and prediction by the Vascular Medicine research group of the University Medical Center Utrecht, The Netherlands (update 22-06-2018):
1. Berkelmans GF, Gudbjörnsdottir S, Franzen S, Svensson AM, van der Graaf Y, Eliasson B, Visseren FL, Dorresteijn JA. Development and validation of a decision support tool for individualizing lifelong lipid, blood pressure, and aspirin treatment in adults with type 2 diabetes mellitus. Submitted
2. Kaasenbrood L, Bhatt DL, Dorresteijn JA, Wilson PW, D’Agostino RB, Massaro JM, van der Graaf Y, Cramer MJ, Kappelle LJ, de Borst GJ, Steg PhG, Visseren FL. Estimated life-expectancy without recurrent cardiovascular events in patients with vascular disease: the REACH-SMART model. Submitted
3. Berkelmans GF, Visseren FL, Jaspers NE, Spiering W, van der Graaf Y, Dorresteijn JA. SPRINT trial: it is not the blood pressure! Eur J Prev Cardiol. 2017 Sep;24(14):1482-1484
4. Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2).
5. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, Visseren FL. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation. 2016 Nov 8;134(19):1419-1429.
6. van der Leeuw J, Visseren FL, Woodward M, van der Graaf Y, Grobbee DE, Harrap S, Heller S, Mancia G, Marre M, Poulter N, Zoungas S, Chalmers J. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. Diabetologia. 2016 Dec;59(12):2603-2612.
7. Stam-Slob MC, Visseren FL, Wouter Jukema J, van der Graaf Y, Poulter NR, Gupta A, Sattar N, Macfarlane PW, Kearney PM, de Craen AJ, Trompet S. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clin Res Cardiol. 2017 Jan;106(1):58-68.
8. van der Sande NG, Dorresteijn JA, Visseren FL, Dwyer JP, Blankestijn PJ, van der Graaf Y, Heerspink HL. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes Obes Metab. 2016 Nov;18(11):1120-1127.
9. van Kruijsdijk RC, Visseren FL, Boni L, Groen HJ, Dingemans AM, Aerts JG, van der Graaf Y, Ardizzoni A, Smit EF. Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction. Ann Oncol. 2016 Jul;27(7):1280-6.
10. Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt SM, Pressel SL, Davis BR, van der Graaf Y, Visseren FL; CARDS, ALLHAT, and ASCOT Investigators. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):213-21.
11. Dorresteijn JA, Kaasenbrood L, Cook NR, van Kruijsdijk RC, van der Graaf Y, Visseren FL, Ridker PM. How to translate clinical trial results into gain in healthy life expectancy for individual patients. BMJ. 2016 Mar 30;352:i1548.
12. Krikke M, Hoogeveen RC, Hoepelman AI, Visseren FL, Arends JE. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models. HIV Med. 2016 Apr;17(4):289-97.
13. van Kruijsdijk RC, Visseren FL, Ridker PM, Dorresteijn JA, Buring JE, van der Graaf Y, Cook NR. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart. 2015 Mar;101(5):369-76.
14. van der Leeuw J, Visseren FL, Woodward M, Zoungas S, Kengne AP, van der Graaf Y, Glasziou P, Hamet P, MacMahon S, Poulter N, Grobbee DE, Chalmers J. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension. 2015 Jan;65(1):115-21.
15. van der Leeuw J, van Dieren S, Beulens JW, Boeing H, Spijkerman AM, van der Graaf Y, van der A DL, Nöthlings U, Visseren FL, Rutten GE, Moons KG, van der Schouw YT, Peelen LM. The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus. Heart. 2015 Feb;101(3):222-9.
16. van der Leeuw J, Ridker PM, van der Graaf Y, Visseren FL. Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. Eur Heart J. 2014 Apr;35(13):837-43.
17. van der Leeuw J, Oemrawsingh RM, van der Graaf Y, Brugts JJ, Deckers JW, Bertrand M, Fox K, Ferrari R, Remme WJ, Simoons ML, Boersma E, Visseren FL. Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA. Int J Cardiol. 2015 Mar 1;182:194-9.
18. Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93.
19. Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM, Cook NR, van der Graaf Y; SMART Study Group. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013 Jun;99(12):866-72.
20. Dorresteijn JA, Visseren FL, Ridker PM, Paynter NP, Wassink AM, Buring JE, van der Graaf Y, Cook NR. Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. Eur Heart J. 2011 Dec;32(23):2962-9.
21. Wassink AM, van der Graaf Y, Janssen KJ, Cook NR, Visseren FL; SMART Study Group. Prediction model with metabolic syndrome to predict recurrent vascular events in patients with clinically manifest vascular diseases. Eur J Prev Cardiol. 2012 Dec;19(6):1486-95.
22. Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg EW, van der Graaf Y, Cook NR. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ. 2011 Oct 3;343:d5888.
23. Jaspers NE, Blaha MJ, Matsushita K, Lehmann N, Erbel RA, van eer Graaf Y, van der Schouw YT, Nambi V, Verschuren WM, Boer JM, Visseren FL, Dorresteijn JA. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation, in apparently healthy people. Submitted.
24. Koopal C, Visseren FL, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC. Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. Diabetes Care. 2018 Jun;41(6):1244-1250.
25. Jaspers NE, Visseren FL, Numans ME, Smulders YM, van Loenen Martinet FA, van der Graaf Y, Dorresteijn JA. Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives. BMJ Open. 2018 May 26;8(5):e021309.
26. Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJ, van der Graaf Y, Dorresteijn JA, Visseren FL. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart. 2018 Apr 5. pii: heartjnl-2017-312510.

This website makes use of cookies

This website shows videos from YouTube and other sources. These parties may place cookies (third party cookies) on your computer. If you do not consent to this you can indicate so here. In this case you will not be able to see any videos from other sources. This website uses cookies for user experience optimization only. Read more on our Cookie policy.

No, I prefer not